7,651.50

+37.50

+0.49%

52,160.00

+242.00

+0.47%

28,795.00

+261.00

+0.91%

Russell 2000 Futures

2,841.30

+20.00

+0.71%

4.9290

-0.0600

-1.20%

18.88

-0.54

-2.78%

3,908.40

+9.50

+0.24%

77,986.31

+6.30

+0.01%

Crude Oil Dec 26

99.67

-4.45

-4.27%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

MIRA Pharmaceuticals, Inc. (MIRA)

0.5485 -0.0231 (-4.04%)

At close: October 30 at 4:00:01 PM EDT

0.5485 0.0000 (0.00%)

Pre-Market: 3:11:59 AM EST

Loading Chart for MIRA

Chart Range Bar

Interval:

In partnership with ChartIQ

MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide

MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide

MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study

MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard

Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard

Mobilize your Website

View Site in Mobile | Classic

Share by: